Abstract
Objective: To evaluate the accuracy of integrated positron emission tomography and computed tomography (PET/CT) using 18-F-fluorodeoxyglucose (FDG), compared with PET alone, in the diagnosis of suspected endometrial cancer recurrence. Methods: Thirty women who had undergone primary surgery for histopathologically proven endometrial cancer with suspected recurrence because of clinical, cytological, biochemical, and/or radiological findings were enrolled in this study. PET and integrated PET/CT images were evaluated by two different experienced radiologists by consensus for each modality. A final diagnosis of recurrence was confirmed by histopathology, other imaging and clinical follow-up for longer than 1 year. The statistical significance of differences between PET and PET/CT was determined by the McNemar test. Results: Patient-based analysis showed that the sensitivity, specificity, and accuracy of PET/CT were 93% (14/15), 93% (14/15), and 93% (28/30), respectively, whereas for PET, the corresponding data were 80% (12/15), 80% (12/15), and 80% (24/30), respectively (P = 0.479, 0.479, and 0.134, respectively). CT from PET/CT resolved the false-positive PET results because of hyper-metabolic activity of benign inflammatory lesions and physiological variants and moreover detected lung metastasis and para-aortic lymph node metastasis that PET missed. However, tiny para-aortic lymph node metastasis could not be detected even with PET/CT. Conclusions: Integrated FDG-PET/CT is a useful complementary modality for providing good anatomic and functional localization of sites of recurrence during follow-up of patients with endometrial cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 103-109 |
| Number of pages | 7 |
| Journal | Annals of Nuclear Medicine |
| Volume | 22 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2008 Feb |
| Externally published | Yes |
Fingerprint
Keywords
- F-FDG
- Endometrial cancer
- PET/CT
- Recurrence
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Cite this
Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer. / Kitajima, Kazuhiro; Murakami, Koji; Yamasaki, Erena; Hagiwara, Shingo; Fukasawa, Ichio; Inaba, Noriyuki; Kaji, Yasushi; Sugimura, Kazuro.
In: Annals of Nuclear Medicine, Vol. 22, No. 2, 02.2008, p. 103-109.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer
AU - Kitajima, Kazuhiro
AU - Murakami, Koji
AU - Yamasaki, Erena
AU - Hagiwara, Shingo
AU - Fukasawa, Ichio
AU - Inaba, Noriyuki
AU - Kaji, Yasushi
AU - Sugimura, Kazuro
PY - 2008/2
Y1 - 2008/2
N2 - Objective: To evaluate the accuracy of integrated positron emission tomography and computed tomography (PET/CT) using 18-F-fluorodeoxyglucose (FDG), compared with PET alone, in the diagnosis of suspected endometrial cancer recurrence. Methods: Thirty women who had undergone primary surgery for histopathologically proven endometrial cancer with suspected recurrence because of clinical, cytological, biochemical, and/or radiological findings were enrolled in this study. PET and integrated PET/CT images were evaluated by two different experienced radiologists by consensus for each modality. A final diagnosis of recurrence was confirmed by histopathology, other imaging and clinical follow-up for longer than 1 year. The statistical significance of differences between PET and PET/CT was determined by the McNemar test. Results: Patient-based analysis showed that the sensitivity, specificity, and accuracy of PET/CT were 93% (14/15), 93% (14/15), and 93% (28/30), respectively, whereas for PET, the corresponding data were 80% (12/15), 80% (12/15), and 80% (24/30), respectively (P = 0.479, 0.479, and 0.134, respectively). CT from PET/CT resolved the false-positive PET results because of hyper-metabolic activity of benign inflammatory lesions and physiological variants and moreover detected lung metastasis and para-aortic lymph node metastasis that PET missed. However, tiny para-aortic lymph node metastasis could not be detected even with PET/CT. Conclusions: Integrated FDG-PET/CT is a useful complementary modality for providing good anatomic and functional localization of sites of recurrence during follow-up of patients with endometrial cancer.
AB - Objective: To evaluate the accuracy of integrated positron emission tomography and computed tomography (PET/CT) using 18-F-fluorodeoxyglucose (FDG), compared with PET alone, in the diagnosis of suspected endometrial cancer recurrence. Methods: Thirty women who had undergone primary surgery for histopathologically proven endometrial cancer with suspected recurrence because of clinical, cytological, biochemical, and/or radiological findings were enrolled in this study. PET and integrated PET/CT images were evaluated by two different experienced radiologists by consensus for each modality. A final diagnosis of recurrence was confirmed by histopathology, other imaging and clinical follow-up for longer than 1 year. The statistical significance of differences between PET and PET/CT was determined by the McNemar test. Results: Patient-based analysis showed that the sensitivity, specificity, and accuracy of PET/CT were 93% (14/15), 93% (14/15), and 93% (28/30), respectively, whereas for PET, the corresponding data were 80% (12/15), 80% (12/15), and 80% (24/30), respectively (P = 0.479, 0.479, and 0.134, respectively). CT from PET/CT resolved the false-positive PET results because of hyper-metabolic activity of benign inflammatory lesions and physiological variants and moreover detected lung metastasis and para-aortic lymph node metastasis that PET missed. However, tiny para-aortic lymph node metastasis could not be detected even with PET/CT. Conclusions: Integrated FDG-PET/CT is a useful complementary modality for providing good anatomic and functional localization of sites of recurrence during follow-up of patients with endometrial cancer.
KW - F-FDG
KW - Endometrial cancer
KW - PET/CT
KW - Recurrence
UR - http://www.scopus.com/inward/record.url?scp=40149092662&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=40149092662&partnerID=8YFLogxK
U2 - 10.1007/s12149-007-0087-y
DO - 10.1007/s12149-007-0087-y
M3 - Article
C2 - 18311534
AN - SCOPUS:40149092662
VL - 22
SP - 103
EP - 109
JO - Annals of Nuclear Medicine
JF - Annals of Nuclear Medicine
SN - 0914-7187
IS - 2
ER -